FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CEO. "We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as e
Related Questions
What is the status of Geron's lead product pipeline (e.g., imetelstat) regarding regulatory milestones and commercial rollout?
What were the year-over-year changes in key financial metrics such as net revenue, operating loss, and cash burn?
Did the company provide guidance for Q3 2025 and full‑year 2025, and how does it compare with prior guidance?
Are there any notable M&A, partnership, or licensing activities announced in the press release?
How does the new sales strategy translate into actual product sales volumes and market share gains?
How does Geron's cash runway look given its current cash position and projected cash burn?
What are the implications of appointing Harout Semerjian as President and CEO on the company's strategic direction?
What are the key risks highlighted in the earnings release, and how might they affect future performance?
How does Geron's performance and valuation compare to other biotech companies focused on hematological malignancies?
How did Geron's Q2 2025 revenue and earnings compare to analysts' consensus estimates?